Please login to the form below

Not currently logged in
Email:
Password:

corruption

This page shows the latest corruption news and features for those working in and with pharma, biotech and healthcare.

Democrats regain control of House in mid-terms

Democrats regain control of House in mid-terms

He was defeated by Democrat Bob Menendez after a closely-fought contest, even though Menendez was tried (but not convicted) on corruption charges last year.

Latest news

More from news
Approximately 10 fully matching, plus 79 partially matching documents found.

Latest Intelligence

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    One of the most serious concerns is bribery, corruption and fraud, well-known problems in the country in recent times. ... So how does AZ ensure it doesn’t get entangled in bribery or corruption in China?

  • Creating a successful global compliance programme Creating a successful global compliance programme

    Article by. partner and global co-chair of Ropes &Gray’s Anti-Corruption &International Risk practice. ... Tina Yu, associate, Ropes &Gray Anti-Corruption &International Risk practice. 9th May 2018.

  • Risky business for pharma Risky business for pharma

    to consider, including but not limited to bribery and corruption, money laundering, competition and antitrust, cybersecurity, data privacy and regulation and compliance. ... especially, but not only, in the US” and he added that “[f] or [GSK], like

  • Stress testing for the perfect compliance storm Stress testing for the perfect compliance storm

    Yet the industry often hits the headlines for all the wrong reasons, with regulators imposing multibillion dollar settlements for compliance failings including corruption and bribery. ... industry. The business model of pharmaceutical and life science

  • Tracking comms trends: tackling reputational issues head on Tracking comms trends: tackling reputational issues head on

    Exploitation. Nightmare. Corruption. These are just three of the words that appear on the first page of results when you Google 'pharmaceutical companies' online.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Is MINT the next BRIC?

    For example: governmental promotion of generics in Brazil, heavy pharmaceutical marketing restrictions in Russia, controversial patent legislation in India and the recent clampdown on industry corruption in China. .

  • Article: The Colombia Conundrum

    Other problems befalling Colombia’s healthcare system include corruption among the EPS providers – 14 out of 22 EPS-C providers have been sanctioned for collusion and there are allegations of fraud, ... drug pricing, as well as a streamlining of the

  • Ageing in China: The Implications for Healthcare

    A hint of this trend is suggested by the ongoing campaign to reduce unnecessary and profit-driven prescriptions, as well as the recent anti-corruption investigations against multinational pharmaceutical companies.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics